Edding Pharm
Latest round
- Series C
Last raised
- Nov 2019
Total raised
- $127M
Investors
- 9
About Edding Pharm
Established in 2001 and based in Shanghai, China, Edding Pharm operates as a new drug developer focusing to the development of new antitumor drugs. It cooperates with GSK and Amarin. In October 2024, it merged with Genor Biopharma Co. The company mainly develops new drugs for three disease areas, which are anti-infection, cardiovascular, and respiratory system. In the field of anti-infection, it has anti-infective drugs Vancocin® and Ceclor®. The Vancocin® is a drug for treating MRSA (Meticillin Resistant Staphylococcus aureus) infection. The Ceclor® is a pediatric antibacterial drug used to treat respiratory infections in pediatric patients. In the field of cardiovascular, the company has Vascepa®, which can be used to reduce cardiovascular risks in targeted high-risk patients. Edding Pharm also provides new antitumor drugs. The company generates revenue by providing new drugs for disease areas such as anti-infection, cardiovascular, respiratory system, and oncology.
Who invested in Edding Pharm
9 investors across 3 rounds
See all investors in Edding Pharm
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Edding Pharm
Who invested in Edding Pharm?
Edding Pharm has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Edding Pharm raised?
Edding Pharm has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Edding Pharm last raise money?
Edding Pharm's most recent round on record is a Series C, in Nov 2019.
What does Edding Pharm do?
Established in 2001 and based in Shanghai, China, Edding Pharm operates as a new drug developer focusing to the development of new antitumor drugs.
Where is Edding Pharm headquartered?
Edding Pharm is headquartered in Shanghai, China.
Which VCs invest in companies like Edding Pharm?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Edding Pharm's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Edding Pharm? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.